The objective of this study is to develop an exploratory design for future Proof-of-Concept
trials which reliably and accurately measure the central nervous system (CNS) effects of
potentially new drugs that oppose the effects of ketamine at a subanesthetic dose level given
to healthy volunteers. A functional magnetic resonance imaging (fMRI) and
electroencephalogram (EEG) performed simultaneously during a ketamine challenge will register
the effects triggered by Ketamine.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.